MDx Firm Prolias Licenses MiRNA IP from Cornell | GenomeWeb

NEW YORK (GenomeWeb News) – Molecular diagnostics company Prolias Technologies today announced it has licensed intellectual property covering microRNA-based diagnostics from Cornell University.

The technologies were developed at the Weill Cornell Medical College. The first series of IP includes a panel called Thymira that differentiates malignant from benign indeterminate thyroid nodules. Prolias, which said it anticipates commercially launching the panel in the coming months, also has licensed an algorithm to interpret results.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: statistical approach to examine intra-tumor heterogeneity, new genetic condition called otulipenia, and more.

Blood tests looking for biomarker changes could catch mental illnesses earlier, Newsweek reports.

DNA testing offers Korean adoptees a way to find their birth parents that sidesteps bureaucratic red tape, according to the New York Times.

A National Institutes of Health researcher has filed an Equal Employment Opportunity complaint against the agency, the Washington Post reports.